Session

IBD (Posters)

LONG-TERM TREATMENT PERSISTENCE WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY
LONG-TERM TREATMENT PERSISTENCE WITH INFLIXIMAB IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A REAL-WORLD STUDY

IBD (Posters)  et al.

PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY
PROGNOSTIC MODEL FOR THE OCCURRENCE OF A COMPOSITE OUTCOME IN CROHN’S DISEASE PATIENTS UNDER INFLIXIMAB MAINTENANCE THERAPY

IBD (Posters)  et al.

SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?
SWITCH FROM INTRAVENOUS TO SUB-CUTANEOUS INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE: WHICH CONSEQUENCES FROM A PHARMACOKINETIC PERSPECTIVE?

IBD (Posters)  et al.

SAFETY OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS:
SAFETY OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS:

IBD (Posters)  et al.

CONTRAST-ENHANCED INTESTINAL ULTRASOUND: TIME TO REFRESH THE NON-INVASIVE MONITORING IN CROHN’S DISEASE
CONTRAST-ENHANCED INTESTINAL ULTRASOUND: TIME TO REFRESH THE NON-INVASIVE MONITORING IN CROHN’S DISEASE

IBD (Posters)  et al.

PLASMA FATTY ACID BINDING PROTEIN 2, INTERLEUKIN-10 AND LIPOPOLYSACCHARIDES AS BIOMARKERS FOR MICROSCOPIC COLITIS
PLASMA FATTY ACID BINDING PROTEIN 2, INTERLEUKIN-10 AND LIPOPOLYSACCHARIDES AS BIOMARKERS FOR MICROSCOPIC COLITIS

IBD (Posters)  et al.

INFLUENCE OF CELIAC DISEASE ON THE COURSE OF INFLAMMATORY BOWEL DISEASE
INFLUENCE OF CELIAC DISEASE ON THE COURSE OF INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY
PREVALENCE OF IRON DEFICIENCY AND ANAEMIA IN THE OUTPATIENT INFLAMMATORY BOWEL DISEASE POPULATION: A DUTCH NATIONAL CROSS-SECTIONAL STUDY

IBD (Posters)  et al.

THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
THE EFFECT OF INDUCTION THERAPY WITH INFLIXIMAB OR VEDOLIZUMAB ON HEPCIDIN AND IRON STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A SUBPOPULATION ANALYSIS OF UNIFI LONG-TERM EXTENSION THROUGH 3 YEARS

IBD (Posters)  et al.

C-REACTIVE PROTEIN/ALBUMIN RATIO (CAR) AS A MARKER FOR DETECTING ACUTE SEVERE ULCERATIVE COLITIS IN EGYPTIAN PATIENTS
C-REACTIVE PROTEIN/ALBUMIN RATIO (CAR) AS A MARKER FOR DETECTING ACUTE SEVERE ULCERATIVE COLITIS IN EGYPTIAN PATIENTS

IBD (Posters)  et al.

LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU
LIVE VACCINES IN CHILDREN EXPOSED TO BIOLOGICAL AGENTS FOR IBD IN UTERO AND/OR DURING BREASTFEEDING: ARE THEY SAFE? RESULTS FROM THE DUMBO REGISTRY OF GETECCU

IBD (Posters)  et al.

SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN’S DISEASE AFTER CYCLOPHOSPHAMIDE-FREE MOBILIZATION: PRELIMINARY RESULTS
SAFETY AND EFFICACY OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN’S DISEASE AFTER CYCLOPHOSPHAMIDE-FREE MOBILIZATION: PRELIMINARY RESULTS

IBD (Posters)  et al.

THE CONTRIBUTION OF THE POLYMORPHISM OF THE ABCB1 GENE IN RESPONSE TO TREATMENT IN TUNISIAN INFLAMMATORY BOWEL DISEASE PATIENTS
THE CONTRIBUTION OF THE POLYMORPHISM OF THE ABCB1 GENE IN RESPONSE TO TREATMENT IN TUNISIAN INFLAMMATORY BOWEL DISEASE PATIENTS

IBD (Posters)  et al.

MRI EVOLUTION AND EFFICACY OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS IN PERIANAL FISTULAE IN CROHN’S DISEASE: RESULTS FROM A PROSPECTIVE MONOCENTRIC STUDY
MRI EVOLUTION AND EFFICACY OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS IN PERIANAL FISTULAE IN CROHN’S DISEASE: RESULTS FROM A PROSPECTIVE MONOCENTRIC STUDY

IBD (Posters)  et al.

SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL
SWITCHING FROM AN INTENSIFIED REGIMEN OF INFLIXIMAB TO A SUBCUTANEOUS STANDARD DOSE IN ADULTS WITH INFLAMMATORY BOWEL DISEASE: OUR EXPERIENCE IN A TERTIARY HOSPITAL

IBD (Posters)  et al.

EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A SUBPOPULATION ANALYSIS OF UNITI/IM-UNITI LONG-TERM EXTENSION THROUGH 5 YEARS
EFFICACY AND SAFETY OF USTEKINUMAB IN ASIAN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: A SUBPOPULATION ANALYSIS OF UNITI/IM-UNITI LONG-TERM EXTENSION THROUGH 5 YEARS

IBD (Posters)  et al.

RISK FACTORS OF CYTOMEGALOVIRUS COLITIS IN INFLAMMATORY BOWEL DISEASE
RISK FACTORS OF CYTOMEGALOVIRUS COLITIS IN INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

OPTIMIZING DUAL-TARGETED THERAPIES IN INFLAMMATORY BOWEL DISEASE VIA MULTIPLE MECHANISMS OF ACTION
OPTIMIZING DUAL-TARGETED THERAPIES IN INFLAMMATORY BOWEL DISEASE VIA MULTIPLE MECHANISMS OF ACTION

IBD (Posters)  et al.

THE EFFECT OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BLOCKING AGENTS ON THE 5- AND 10-YEAR DISEASE COURSE OF CROHN’S DISEASE PATIENTS WITH HYPERTENSION
THE EFFECT OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM BLOCKING AGENTS ON THE 5- AND 10-YEAR DISEASE COURSE OF CROHN’S DISEASE PATIENTS WITH HYPERTENSION

IBD (Posters)  et al.

Item 441 - 460 / 612
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
23
24 25 26 27 28 29 30 31